Quebec ERs are overflowing before flu season hits its peak

Quebec emergency departments are overcrowded ahead of the expected influenza peak around Dec. 25-26, with nearly 1 in 5 ER patients leaving without seeing a doctor and about 3,500 influenza cases recently reported; 26% of tests for influenza A (H3N2) are positive and national positivity was 27.7% last week. Children (age 5–17) and older adults are driving spread and severe presentations, at least eight measles cases have been reported, and health officials warn holiday staffing shortages and parental illness are intensifying pressure on hospitals while urging targeted ER use, masking and use of clinics or nurse advice lines.

Analysis

Market structure: The immediate winners are telemedicine and diagnostic/testing providers (higher visit + test volumes) and OTC/consumer-health firms; losers are hospital elective-care revenue and strained provincial health budgets. With influenza A (H3N2) positivity ~26–28% and cases front‑loaded before Dec 25–26, expect a 2–6 week surge in urgent-care demand that shifts incremental volumes from ERs to virtual/clinic channels, improving pricing power for telehealth and labs while compressing hospital throughput and per‑case margins.

Risk assessment: Tail risks include a hospital-capacity threshold breach (e.g., >95% ED occupancy) triggering emergency provincial purchases, stricter mandates, or school closures that amplify absenteeism and short GDP blips. Time horizons: immediate (days–weeks) sees volume spikes and revenue bump for labs/telehealth; short term (1–3 months) may show margin pressure for hospitals and higher public spending; long term (quarters) depends on vaccine uptake and recurring H3N2 cycles. Key catalysts: national positivity >30% or reported hospital diversion orders.

Trade implications: Favor short-duration, event-driven longs in telemedicine (TDOC) and diagnostics (LH, DGX) and consumer staples (PG, JNJ) via call spreads; selectively reduce exposure to hospital operators/REITs (HCA, MPW). Use pair trades: long LH/DGX vs short HCA to capture relative volume/margin divergence. Trade sizing should be small (1–3% portfolio), target +15–40% move in 2–8 weeks, stop-loss 30%.

Contrarian angles: Consensus understates persistent behavioral change — parents and seniors adopting telehealth post‑holiday could lift baseline telemedicine revenue by ~5–10% next quarter, an underpriced recurring benefit. The market may over-penalize hospitals for temporary strain; short hospital positions must be timed and limited because rebound in elective procedures can revalue names within 1–3 months. Historical parallels (severe seasonal flu years) show OTC and telehealth spikes are front-loaded and decay after 6–12 weeks, favoring short-duration option strategies.

Key Decisions for Investors

• Establish a 2% portfolio long via Teladoc Health (TDOC) 2–4 week near‑ATM call spread (expiry Jan 2026) to capture holiday surge; target +30% upside, cut at -30% loss or roll if positivity >30%.
• Allocate 1–2% long to diagnostics: buy LabCorp (LH) or Quest Diagnostics (DGX) outright (1% each max) or 6–8 week call spreads; take profits if weekly test‑volume growth normalizes (<5% week‑over‑week).
• Pair trade: long Procter & Gamble (PG) 1% (OTC cold/care sales) and short HCA Healthcare (HCA) 1% to capture relative outperformance; set a profit target of +20% on the spread and stop-loss if HCA falls >25% or signs of government relief emerge.
• Reduce tactical exposure to hospital REITs/ops (e.g., MPW, HCA) by 1–3% of portfolio and redeploy into consumer staples (PG, JNJ) and telemedicine; reassess in 6–12 weeks when elective procedure volumes normalize.
• Monitor triggers for escalation: if provincial/national influenza positivity >30% or ED occupancy >95% in Quebec, scale long telehealth/diagnostics positions by another 0.5–1% each within 3–7 days.